On the 9 February, the Transparency Commission of the French National Authority for Health published its advice on Zonegran (zonisamide) in its new indication for the treatment of partial seizures in adolescents and children from 6 years of age. Zonisamide, a novel anti-epileptic drug (AED) with a multimodal mechanism of action and a chemical structure unrelated to any other AED, was already indicated in Europe as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; and as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults. Now, adolescents and children from 6 years of age will be able to benefit from this treatment as an adjunctive therapy.

For more details, go to: http://www.prnewswire.co.uk/news-releases/eisais-epilepsy-treatment-zonegran-zonisamide-approved-for-use-in-children-and-adolescents-in-france-292290851.html